ライフサイエンスコーパス: menarche

1 ere positively associated with risk of early menarche.

2 nger among women who had been exposed before menarche.

3 s at 106 genomic loci associated with age at menarche.

4 , used a lactation suppressant, or had early menarche.

5 menopause and 22,240 (22%) experienced early menarche.

6 diovascular disease, hypertension, and early menarche.

7 ere not significantly associated with age of menarche.

8 ploratory analyses (n = 113) examined age at menarche.

9 data among participants who had not reached menarche.

10 g cellular differentiation and the timing of menarche.

11 on, daytime somnolence, epilepsy and earlier menarche.

12 amin D deficiency is associated with earlier menarche.

13 sun exposure, is inversely related to age at menarche.

14 ne of the fastest rates of decline in age at menarche.

15 eriodically about the occurrence and date of menarche.

16 sis of self-reported Tanner stage and age at menarche.

17 locus in regulating height and the timing of menarche.

18 gain, may be associated with earlier age at menarche.

19 dult BMI was robust to adjustment for age at menarche.

20 ion of genetic influences on CD by timing of menarche.

21 of etiological moderation of CD by timing of menarche.

22 ohorts, despite stability in the mean age at menarche.

23 intakes were associated with a later age at menarche.

24 , total cholesterol, and (in females) age at menarche.

25 risk factors, such as ages at menopause and menarche.

26 , sucrose, fructose, and aspartame and early menarche.

27 hood is associated with higher risk of early menarche.

28 s conducted in women more than 2 years after menarche (177 lamotrigine, (HA) 186 valproate) to exclud

29 ner 5, -2.5 months, 95% CI: -4.1, -1.0), and menarche (-3.1 months, 95% CI: -4.0, -2.3).

30 g. mean difference in LV mass per year later menarche: -4.2 g (95% CI:-7.0,-1.4) reducing to -2.2 g (

31 llele was associated with 0.12 years earlier menarche (95% CI = 0.08-0.16; P = 2.8 x 10(-10); combine

32 bertal timing variants associate with age at menarche, a late manifestation of puberty, and body mass

33 ependent signals (P < 5 x 10(-8)) for age at menarche, a milestone in female pubertal development.

34 ast composition at Tanner stage 4 and age at menarche.A total of 515 Chilean girls are included in th

35 between puberty timing, particularly age at menarche (AAM), and type 2 diabetes.

36 d be emphasized when addressing early age at menarche across cultures.

37 ion within 5 years of cancer diagnosis or no menarche after cancer treatment by the age of 18 years.

38 nt for smoking, physical activity and age at menarche, after exclusion of 3% of females with the high

39 d soft drinks and early menarche (defined as menarche age <11 y).

40 were particularly marked in women with early menarche (age <12.5 years).

41 Associations were similar for race, age at menarche, age at first birth, family history, alcohol co

42 psy, body mass index at age 18 years, age at menarche, age at first birth, oral contraceptive use, bi

43 rnal self-reported age at conception, age at menarche, age at first birth, parity, and gravidity.

44 east disease, height at age 25 years, age at menarche, age at menopause, age at first birth, and pari

45 uthors investigated secular trends in age at menarche, age at menopause, and reproductive life span w

46 Breast cancer risks associated with age at menarche, age at menopause, breastfeeding, age at first

47 Subgroup analyses by age, age at menarche, age at menopause, menopausal status, number of

48 , oral contraceptive use or duration, age at menarche, age at menopause, or history of hysterectomy o

49 include inherited genetic mutations, age of menarche, age of menopause, and parity.

50 Compared to those with menarche aged <14, the age-adjusted odds ratios for HSV-

51 ), 0.71 (0.57-0.89) and 0.69 (0.54-0.89) for menarche aged 14, 15 and 16+ respectively.

52 iations between the selected SNPs and age at menarche (ages 9-17 years) using linear regression model

53 (BMI), smoking, alcohol drinking and age at menarche (all nominal P < 0.05).

54 narche on adult sleep duration, since age of menarche also affects obesity, our novel finding may be

55 5% confidence interval: 1.12, 4.40) of early menarche among daughters of mothers who were single pare

56 Age at menarche among women with MS was generally lower than th

57 only the inverse association between age at menarche and adult BMI remained.

58 , after excluding those that had not started menarche and after excluding those using hormonal contra

59 rs conclude that the interval between age at menarche and age at first birth is associated with the r

60 Age at menarche and age at natural menopause are associated wit

61 ociation studies, including those for age at menarche and cardiometabolic traits.

62 nd no evidence of association between age at menarche and death from all cardiovascular diseases or s

63 An inverse association between age at menarche and death from IHD was observed only among nons

64 her reports of an association between age at menarche and fibroid development (regardless of characte

65 used to estimate associations between age at menarche and fibroid status and to test for interactions

66 Ages at menarche and first birth are established risk factors fo

67 terval of > or =16 years between the ages of menarche and first birth had 1.5-fold (95% confidence in

68 3% increase per pack-year of smoking between menarche and first childbirth (relative risk = 1.03, 95%

69 is associated with a short interval between menarche and first sexual intercourse (FSI).

70 The mean age of menarche and FSI was 12.4 and 16.0 years, respectively.

71 A short interval between menarche and FSI was a risk factor for cytologic abnorma

72 16/18 vaccine had nonmissing data for age of menarche and FSI.

73 ed to examine the association between age at menarche and gestational diabetes mellitus (GDM).

74 and two genetic risk scores, GRS1 for age at menarche and GRS2 for age at menopause.

75 Earlier menarche and irregular periods, among other markers of s

76 can exhibit acute pelvic pain shortly after menarche and may show non-specific and variable symptoms

77 djusted relative risks (RRs) associated with menarche and menopause for breast cancer overall, and by

78 Menarche and menopause mark the onset and cessation, res

79 The effects of menarche and menopause on breast cancer risk might not b

80 ual and reproductive features, e.g., ages at menarche and menopause, are found to be associated with

81 ximately 50% of the variation in both age at menarche and menopause, but to date the known genes expl

82 ed with reproductive traits, such as ages of menarche and menopause, in women of European ancestry.

83 no association between prognosis and age at menarche and menopause, menopausal status at diagnosis,

84 ions of female reproductive factors (ages at menarche and menopause, menopausal status, use of oral c

85 survival of variables related to pregnancy, menarche and menopause, prior use of exogenous hormones,

86 served an inverse association between age at menarche and MS risk.

87 ssed the possible association between age at menarche and multiple sclerosis (MS), and results are co

88 The observed associations with age at menarche and oral contraceptive use warrant further inve

89 which has been recently implicated in age of menarche and other phenotypes.

90 Age at menarche and other reproductive factors were not associa

91 uggest complex genetic relationships between menarche and overall obesity, and to a lesser extent cen

92 did not observe interactions between age at menarche and race.

93 method using the relationship between age at menarche and risk of breast cancer, with body mass index

94 Associations between age at menarche and risk of MS were evaluated with hazard ratio

95 investigated the association between age at menarche and risk of type 2 diabetes mellitus (T2DM) amo

96 e is known about associations between age at menarche and sexually transmitted infections, although g

97 e the role of early-life exposures in age at menarche and subsequent GDM risk.

98 ce, rather than a determinant, of the age at menarche and that secular changes in BMI and in the mean

99 od BMI seems to contribute to earlier age at menarche and, because of tracking, greater adult BMI and

100 interpretations of the impact of precocious menarche and, to a lesser extent, delayed menarche on CD

101 including parity, age at first birth, age at menarche, and age at menopause) with risk of colorectal

102 contraceptive use, cigarette smoking, age at menarche, and diabetes were associated with type I and t

103 e analysis of documented infertility, age at menarche, and family history did not show allelic associ

104 4-1.057; p<0.0001) for every year younger at menarche, and independently by a smaller amount (1.029,

105 ations of parity, age at first birth, age at menarche, and menopausal status with percent density and

106 MEM38B, ZNF483, NFAT5 and OLFM2) with age at menarche, and of two loci (MCM8 and BRSK1/TMEM150B) with

107 Higher premenarcheal BMI predicted earlier menarche, and the strong association between premenarche

108 Early age at menarche appears to be associated with an increased risk

109 comprehensive genome-wide studies of age at menarche are lacking for AA women.

110 t past, such as age at first birth or age at menarche, are less predictive of late-life breast cancer

111 dence interval, 1.22-1.31; P<0.0001) and for menarche at >/=17 years of age was 1.23 (95% confidence

112 ears, the adjusted relative risk for CHD for menarche at </=10 years of age was 1.27 (95% confidence

113 arche (<12 years of age), those who reported menarche at 12-13 years of age or at 14 years of age or

114 Compared with women with menarche at 13 years, the adjusted relative risk for CHD

115 Compared with women with menarche at age 13 years, women who had their first mens

116 che (at <12 years of age) versus "not early" menarche (at >/= 12 years of age) (pooled hazard ratio =

117 m all causes for women who experienced early menarche (at <12 years of age) versus "not early" menarc

118 Seven percent underwent menarche before 11 years of age and 11% at 15 years or l

119 rity (90.7%) of girls in our cohort attained menarche before the data analyses with a mean +/- SD age

120 risk was U shaped, with both early and late menarche being associated with increased risk.

121 han 100 loci have been identified for age at menarche by genome-wide association studies; however, co

122 and EGR-1 acts with NAB proteins to initiate menarche by regulating the transcription of the luteiniz

123 Relative risks of T2DM across age-at-menarche categories (< or =11, 12, 13, 14, and > or =15

124 ly 7.4% of the population variance in age at menarche, corresponding to approximately 25% of the esti

125 LDL, TGs, body mass index (BMI), and age at menarche, corroborated this observation for HDL (OR = 1.

126 ecular changes in BMI and in the mean age at menarche could be independent phenomena.

127 adequate menstrual history (including age at menarche, current menstrual status, age at last menstrua

128 1-2 y until age 21-25 y; pubertal status and menarche data were collected.

129 After adjusting for maternal age at menarche, daughter's age, and body mass index at baselin

130 The mean age at menarche decreased by approximately 6 months for those b

131 artificially sweetened soft drinks and early menarche (defined as menarche age <11 y).

132 rls assigned to composites had lower risk of menarche during follow-up (hazard ratio = 0.57, 95% CI 0

133 rls in the vitamin D-deficient group reached menarche during follow-up compared with 23% of girls in

134 with higher serum FSH levels, earlier age at menarche, earlier age at first child, higher lifetime pa

135 the heritability of body mass index, age at menarche, educational attainment and smoking behavior.

136 )/height (m)(2)) on the probability of early menarche, estimates and standard errors from an automate

137 to 1 year was associated with earlier age at menarche even after adjustment for later childhood growt

138 ody size changes were associated with age at menarche even after considering later childhood body siz

139 cycles that regularized within 2 years after menarche, fecundability ratios for cycles that regulariz

140 ely examined the relationship between age at menarche, fibroid characteristics, and race.

141 Age at menarche, first and last live birth, and menopause; numb

142 er of reproductive years (subtracting age at menarche from age at natural menopause), from 36.1 years

143 vely) after adjustment for age, race, age at menarche, gamma-tocopherol, beta-carotene, total cholest

144 agnosed in 11% (n = 70) of women with age at menarche greater than or equal to 13 years compared with

145 with those who had an average-to-late age at menarche (>/= 11 years).

146 f menarche, those with FSI within 3 years of menarche had a greater risk of cytologic abnormalities (

147 Early age at menarche had a similar positive association in individua

148 thern Malawi we show that those with earlier menarche had earlier sexual debut, earlier marriage and

149 Genetically-predicted age at menarche had no robust association but genetically-predi

150 mmon genetic variants associated with age at menarche has a potential value in pointing to the geneti

151 Earlier age at menarche has been associated with higher risk of coronar

152 Early menarche has been associated with increased risk of coro

153 Age at menarche has been associated with several reproductive c

154 Early menarche has been linked to risk of several chronic dise

155 The observed age of menarche has fallen, which may have important adverse so

156 for menstrual cycle regularity shortly after menarche, having a cessation of menstruation, use of ano

157 4-DCP) were inversely associated with age of menarche [hazard ratios of 1.10; 95% confidence interval

158 odifiable factors were included: age, age at menarche, height, a combination of parity and age at fir

159 M occurs almost exclusively in females after menarche, highlighting the central but as yet poorly und

160 Late age at menarche, hormone replacement therapy use, and Hispanic

161 s parity, age at first birth, breastfeeding, menarche, hormone replacement therapy use, somatotype at

162 nt genome-wide association studies of age at menarche identified several obesity-related variants.

163 ongest (67%) in girls with average timing of menarche (ie, age 12-13 years) and substantially weaker

164 tion data to detect genes influencing age at menarche in 17,510 women.

165 t a genome-wide association study for age at menarche in 4,714 women and report an association in LIN

166 ife and socioeconomic environment and age at menarche in 523 girls.

167 -nucleotide polymorphisms (SNPs) with age at menarche in 92,116 women of European descent from 38 stu

168 se, and hypertensive disease risks by age at menarche in a large prospective study of UK women.

169 tween vitamin D status and the occurrence of menarche in a prospective study in girls from Bogota, Co

170 was positively associated with risk of early menarche in a US cohort of African American and Caucasia

171 ained variants significantly associated with menarche in AA women.

172 tionship between EDC exposure and the age of menarche in adolescent girls.

173 sociated with a lower FGV and delayed age at menarche in Chilean girls.

174 l selection may have favored a higher age at menarche in females.

175 Age at menarche in girls, and age at spermarche in boys, did no

176 olescent obesity include earlier puberty and menarche in girls, type 2 diabetes and increased inciden

177 ge at puberty in the pig and loci for age at menarche in humans.

178 e environment and single parenting on age at menarche in Mexican Americans.

179 2,5-DCP, a potential EDC, and earlier age of menarche in the general U.S. population.

180 The estimated mean (+/-SE) ages at menarche in the same groups were 11.8 +/- 0.2 y and 12.6

181 d the role of psychosocial factors on age at menarche in this population.

182 es are established in adolescence, and later menarche in women is associated with delayed mutation ac

183 inverse variance weighting, later of age at menarche increased adult sleep duration [0.020 per categ

184 rregular menstrual cycles and earlier age at menarche increased the risk of RA.

185 The impact of menarche interval on the odds of developing CIN2-3/AIS w

186 Other traits, such as age at menarche, IQ and lifespan, which have been changing duri

187 For girls treated before menarche, irradiation of the uterus and ovaries at doses

188 thors investigated the association of age at menarche, irregular periods, duration of menstruation, a

189 Age at menarche is a marker of timing of puberty in females.

190 Early menarche is a risk factor for cardiometabolic disease an

191 women of European ancestry (EA), and earlier menarche is a risk factor for obesity and type 2 diabete

192 It is unclear whether age at menarche is an independent determinant of future cardiov

193 These data suggest that early menarche is associated with increased risk of T2DM in ad

194 size changes are also associated with age at menarche is less clear.

195 These findings suggest that early menarche is only a risk marker.

196 ctive axis, is associated with risk of early menarche is sparse.

197 red with 12.6% (n = 57) of women with age at menarche less than 13 years (incidence rate per 100 pers

198 2 (P = 2.2 x 10(3)(3)), we identified 30 new menarche loci (all P < 5 x 10) and found suggestive evid

199 e, our results indicate that a proportion of menarche loci are important for pubertal initiation in b

200 t evidence of cross-ethnic generalization of menarche loci identified to date, and suggest a number o

201 tigation of SNPs in 42 previously identified menarche loci in EA women demonstrated that 25 (60%) of

202 yocardin-like 2 (MKL2) (P = 8.9 x 10(-9)), a menarche locus tagging a developmental pathway linking e

203 Age at menarche < or =10 years was associated with an increased

204 nificantly associated with an earlier age at menarche (< 11 years).

205 Compared with women who had an early age at menarche (<12 years of age), those who reported menarche

206 Our findings indicate that a young age at menarche may identify women at higher risk of GDM.

207 TCDD exposure, particularly exposure before menarche, may have enduring impacts on women's total thy

208 n smoking, hormonal use, diabetes and age at menarche/menopause was obtained for all individuals.

209 gnancy status, number of live births, age at menarche, menstrual irregularity, age at first birth, st

210 C6A/TACR3/PRKAG1) are associated with age at menarche (minor allele frequencies 0.08-4.6%; effect siz

211 ass (assumed to occur 2 years after onset of menarche) modified the association.

212 he extra vulnerability of girls with earlier menarche needs to be recognised.

213 Incident early menarche occurred in 165 (8.3%) of the girls.

214 Earlier age at menarche (odds ratio = 1.03, confidence interval: 1.01,

215 the data analyses with a mean +/- SD age at menarche of 11.9 +/- 0.7 y.

216 An independent effect of early menarche on adult adiposity cannot be excluded, but it i

217 study demonstrated a causal effect of age at menarche on adult sleep duration, since age of menarche

218 African-American (AA) women have earlier menarche on average than women of European ancestry (EA)

219 us menarche and, to a lesser extent, delayed menarche on CD development.

220 ow an inverse direct causal effect of age at menarche on risk of breast cancer (independent of BMI),

221 fication of causal effects of BMI and age-at-menarche on the risk of breast cancer; no causal effect

222 ular, girls who consumed >125 g yogurt/d had menarche, on average, 4.6 mo (95% CI: 1.9, 7.4 mo) later

223 It presents soon after menarche or shows delayed presentation depending on the

224 ner stages, axillary hair growth, and age at menarche or voice break and first ejaculation-every 6 mo

225 Early age at menarche, oral contraceptive use, early age at menopause

226 seen with parity/age at first birth, age at menarche, oral contraceptive use, family history of brea

227 Age at menarche, oral contraceptive use, pregnancy, parity, age

228 Older age at menopause (P = 0.007), earlier menarche (P = 0.007), and shorter duration of OC use (P

229 or postmenopausal obesity (P = 0.02), age at menarche (P = 0.05), age at first birth (P = 0.04), and

230 ociation was observed with increasing age at menarche (P for trend = 0.02) and increasing years of or

231 ation factor were also associated with early menarche (P heterogeneity < 0.0001), and in contrast to

232 ade (P heterogeneity = 0.02), younger age at menarche (P heterogeneity = 0.04), lower current body ma

233 Older age at menopause (p=0.007), earlier menarche (p=0.007), and shorter duration of OC use (p=0.

234 (p.W275X) is associated with 1.25-year-later menarche (P=2.8 x 10(-11)), illustrating the utility of

235 n usually have progressive pelvic pain after menarche, palpable mass due to hemihaemato(metro)colpos

236 served no significant associations of age at menarche, parity, age at first birth, and exogenous horm

237 tablished environmental risk factors (age at menarche, parity, age at first birth, breastfeeding, men

238 Risk of BCC was not associated with age at menarche, parity, age at first birth, infertility, use o

239 hed BC risk (body mass index, height, age at menarche, parity, age at menopause, smoking, alcohol and

240 Other factors, including smoking, age at menarche, parity, and body mass index, did not significa

241 Reproductive factors, including age at menarche, parity, breastfeeding, and age at menopause, w

242 icant associations were observed with age at menarche, parity, lactation, oral contraceptive use, or

243 No association was found between age at menarche, parity, oral contraceptive use, estrogen repla

244 e and other risk factors, age<or=10 years at menarche (pooled RR 2.1, 95% confidence interval [95% CI

245 For each 1-year increase in age at menarche, risk of MS was reduced by 13% (hazard ratio =

246 2 = 85.4%) and higher for early versus later menarche (RR = 1.39, 95% CI 1.25-1.55, p < 0.001, 23 est

247 was not significantly associated with early menarche (RR for 1 serving/d increment: 0.88; 95% CI: 0.

248 lso positively associated with risk of early menarche (RR for 1 serving/d increment: 1.43; 95% CI: 1.

249 s was associated with a higher risk of early menarche (RR for 1 serving/d increment: 1.47; 95% CI: 1.

250 12 estimates, n = 852,268, I2 = 51.8%; early menarche: RR = 1.19, 95% CI 1.11-1.28, p < 0.001, 21 est

251 distributions than Caucasians, such as later menarche, shorter stature, higher parity, earlier age at

252 imal radius BMD, according to the time since menarche, showed a highly significant effect of suppleme

253 Menarche signals were enriched in imprinted regions, wit

254 ses adjusted for energy, age, and time since menarche, significant correlations (P < 0.05) were as fo

255 al (body size, pregnancy weight gain, age at menarche, smoking) and birth (birth weight, birth length

256 ection for premenopausal women) minus age at menarche, subtracting years of oral contraceptive (OC) u

257 tted infections, although girls with earlier menarche tend to have earlier sexual debut and school dr

258 The event of menarche tends to coincide with girls' transitions from

259 rls with data on prospective diet and age at menarche.The mean +/- SD breast FGV and percentage of fi

260 th women who postponed FSI beyond 3 years of menarche, those with FSI within 3 years of menarche had

261 Age at menarche, time to menstrual regularization, and duration

262 uggest a number of novel biological links to menarche timing in AA women.

263 synthesis as biological processes related to menarche timing.

264 longer reproductive lifespan, roughly age of menarche to age of menopause or lifetime ovulatory cycle

265 e span-roughly determined as the period from menarche to menopause or lifetime number of ovulatory cy

266 , and total reproductive duration [time from menarche to menopause]) were self-reported at study base

267 tify the underlying mechanisms linking early menarche to T2D/IGT risk.

268 In this cohort, the relation of age at menarche to vascular disease risk was U shaped, with bot

269 e risk of T2D in white UK women due to early menarche unadjusted and adjusted for adiposity was 12.6%

270 Outcomes were age at menarche, voice break, first ejaculation, and Tanner sta

271 The weighted mean age of menarche was 12.0 years of age.

272 Mean age at menarche was 12.9 years (standard deviation, 1.4).

273 s showed that each 1-year increase in age at menarche was associated with a 3% lower relative risk of

274 Regression models found that earlier menarche was associated with higher (more adverse) LV ma

275 Young age at menarche was associated with increased risk of T2DM afte

276 en of 1997", cross-sectionally, older age of menarche was associated with longer (9+ hours) sleep dur

277 Younger age at menarche was associated with risk only in white women.

278 The incidence of menarche was compared between groups by using time-to-ev

279 Early menarche was consistently associated with higher risk of

280 A 1-year increase in age at menarche was inversely associated with fibroids (adjuste

281 Early menarche was not associated with increased risk of AAA.

282 A decline in the age at menarche was recently reported for US girls.

283 Age at menarche was reported at baseline in 2000 when women wer

284 The date of menarche was reported every 6 mo.

285 oportional hazards model, the probability of menarche was twice as high in vitamin D-deficient girls

286 fference between age at menopause and age at menarche, was used as a proxy of duration of exposure to

287 For age at menarche, we identified ten associated SNPs (P = 1 x 10(

288 To identify loci for age at menarche, we performed a meta-analysis of 32 genome-wide

289 es that regularized 2-3 and >/=4 years after menarche were 0.90 (95% CI: 0.80, 1.02) and 0.89 (95% CI

290 Menarcheal status and age at menarche were assessed via the Pubertal Development Scal

291 iously reported to be associated with age at menarche were confirmed, but none of the central adiposi

292 ciations of body mass index loci with age at menarche were identified, and 11 adiposity loci previous

293 magnitudes of these risks for early and late menarche were smaller than those for CHD.

294 childhood is correlated with earlier age at menarche; whether birth and infant body size changes are

295 height is positively correlated with age at menarche, which in turn is negatively associated with br

296 oportion of T2D in women is related to early menarche, which would be expected to increase in light o

297 , smoking, alcohol intake, parity and age at menarche with changes in hormones by reproductive age.

298 ome-wide association of self-reported age at menarche with common single-nucleotide polymorphisms (SN

299 ctors, such as premature menopause and early menarche, with risk of AAA in a large, ethnically divers

300 ection for premenopausal women) minus age at menarche, years of oral contraceptive (OC) use, and one